



# Health Care Update

OCTOBER 15, 2024





- Public Comment
- Financials (Rae-Ellen)
- Partnership (Bernie)
- High-level utilization (Josh)
- MAPD Premium Adjustment (Rae-Ellen)
- Communications (Betsy)
- 12-month data for Intellihealth (Josh)



# Public Comment



<b>FY 2024-2025 Anticipated Year End Health Account Balances</b>	
Budget Review 9.15.24	
<b>Active Employee Healthcare Appropriation</b>	
<b>Projected Appropriation Balance:</b>	<b>\$ 14,307,686.14</b>
<b>Active Employee Healthcare FAD Accounts</b>	
Projected Active Health FAD	\$ 133,265,647.04
Projected Active Rx FAD	\$ 13,015,856.92
<b>Combined FAD Balances:</b>	<b>\$ 146,281,503.96</b>
<b>Retired Employee Healthcare Appropriation</b>	
<b>Projected Appropriation Balance:</b>	<b>\$ -37,406,075.39</b>
<b>Retired Employee Healthcare OPEB FAD Accounts</b>	
Projected Retiree Health	\$ 194,708,691.16
Projected Retiree Rx	\$ 43,675,483.67
<b>Combined FAD Balances:</b>	<b>\$ 238,384,174.82</b>



## Partnership 2.0

As of 10/1/24 we have 168 groups enrolled totaling over 25,000 employees and just over 60,000 members.

- Reached out to existing group leads regarding the additional increase (rerate) in the Medicare Advantage Plan
  - Groups had until Friday 10/11 to advise if they will be leaving the plan
  - 2 Groups had decided to leave the MAPD plan only

## Partnership 1.0

As of 10/1/24 we still have 5 groups remaining totaling approximately 2,500 employees and 3,500 members.

# Actives & Non-Medicare Retirees


## All Plans

### Claims Summary<sup>1</sup>

	Total Cost (PMPM)	% of Total Cost	Current Trend
<b>Medical</b>	<b>\$740.14</b>	<b>82%</b>	<b>▲ 5.0%</b>
Inpatient Facility	\$148.56	17%	▲ 6.7%
Outpatient Facility	\$291.88	32%	▲ 4.9%
Professional Services	\$277.62	31%	▲ 4.2%
Ancillary	\$22.09	2%	▲ 4.7%
<b>Pharmacy<sup>2</sup></b>	<b>\$158.37</b>	<b>18%</b>	<b>▲ 9.3%</b>
<b>Total Cost</b>	<b>\$898.51</b>		<b>▲ 5.7%</b>

### Drivers of Trend

Service Category	Current PMPM	Prior PMPM	Change
Prescription Drugs - Brand	\$89.00	\$78.70	▲ \$10.30
Inpatient - Medical	\$45.62	\$38.22	▲ \$7.40
Outpatient - Surgery	\$92.64	\$85.52	▲ \$7.12
Outpatient - Pharmacy	\$53.91	\$50.80	▲ \$3.11
Professional -E&M	\$51.25	\$48.23	▲ \$3.02



### Observations

- PMPM medical costs have increased 5.0% Year-over-Year (“YoY”) and accounted for 82% of total spend.
- PMPMRx costs have increased 9.3% YoY and accounted for 18% of total spend.
- The second table above illustrates the top 5 drivers of trend. Prescription Drugs - Brand was the top driver of spend on a PMPM basis, increasing \$10.30 PMPM over last year.

<sup>1</sup> Reflects paid claims through August 2024. Claims for the current period have been completed using a factor of 0.95

<sup>2</sup> Pharmacy costs reflect PrudentRx savings.

# MAPD Premium Adjustment



## Contract Stipulation - Population Growth

- Aetna reserves the right to re-rate or restructure the rating if the total enrollment varies by +/- 10 percent from that assumed when rating the case.
  - At the time of initial rating during contracting in 2022, the State of CT and CT Partnership MAPD Plan covered 55,874 lives.
  - At the launch of the plan on January 1, 2023, the total plan enrollment was approximately 60,000 lives
  - As of today, the total plan covers 63,745 lives; an increase of 14% over the initial rating population.

## Re-Rating Factors

- Population
- Medicare Subsidy Reduction
- Market Changes
- Plan Performance

## Premium Adjustment

- \$339 PMPM New Rate effective January 1, 2025
- \$191.25 PMPM Current Rate
- \$258.08 PMPM Initial Renewal Rate

# Monthly All-User Email Impact



Email Topic	Sent*/Group	Open Rate	CTOR
<b>Wellbeing/Chronic Condition (HEP)</b> Presented by WellSpark + Upswing Health + Spotlight	State - Sept 4	17%	9%
	State personal - Sept 4	45%	2%
	SPP - Sept 4	45%	4%
<b>Benefits Spotlight Series*</b> on-demand link sent to registrants' email for the Sept event on 9/27	State - Sept 10 + 19	17%	9%
	State personal - Sept 11 +19	46%	2%
	SPP - Sept 11 + 19	52%	3%
<b>Flu Shot</b>	State - Sept 18	18%	4%
	State personal - Sept 18	44%	2%
	SPP - Sept 18	45%	2%
<b>Diabetes Prevention Program (DPP)</b> Class #13 registration	State – Sept 24	19%	6%
	State personal – Sept 24	44%	3%
	SPP - Sept 24	47%	4%




**\*Quantum Health Spotlight Benefits Portal + Find Provider tool HEP**

- 656 Registered for this spotlight
- 317 unique viewers attended
- 192 have viewed the YouTube recording



## Sept-Oct Portal Sliders: Flu, Find Provider tool, HEP



Open Rate = Unique Opens / Deliveries; Industry standard = 23.7%; CTOR = Unique Clicks / Unique Opens; Industry Standard = 13.4%; Emails were also sent to agency/group benefit contacts, call centers, Judicial and Higher Ed, HCCC representatives' \*\*Facebook posts created and boosted (ads) to align with all-user topics each month; additional' marketing may include a slider featured on the QH benefits portal




# Flyte 12 Month Results

---



**47** Average Age




Average Self-Reported **Baseline Weight** **223.9 lbs**

Average Self-Reported **Baseline BMI** **36.4**

*\*As of 6/30/2024 based on available self-reported, demographic data  
\*\* Note: Sex at birth is not required at the time of application*

# Path to First Appointment




\*As of 6/30/2024


# Current Medications Utilization

6,188 Unique Filled Prescriptions


Filled Medications by Type



GLP-1 Medication Utilization by Name



Non GLP-1 AOM Medication Utilization by Name



- Ozempic accounted for greater than two-thirds of all GLP-1 prescriptions
- Mounjaro and Rybelsus accounted for the vast majority of the remaining third

- Extremely limited use of the most expensive GLP-1s
- Very limited use of Wegovy; only for a subset of pre-existing users
- Zepbound not used at all by Flyte clinicians

\*As of 6/30/2024



# Weight

## Average Weight


At enrollment, for patients with appointments

227.9 lbs

n= 4608 PATIENTS

## Weight Change Over Time

For patients who have been enrolled  $\geq 12$  months and have data available



% change ↓ 16.6%


n= 563 PATIENTS

\*As of 6/30/2024

# 12 Month Enrollment Weight Loss

## Patients on a GLP-1 vs Non GLP-1 AOMs

For patients who have been enrolled  $\geq 12$  months, weight data is available, and were *prescribed* a medication by a Flyte Provider



A large subset of patients in this cohort were already on a GLP-1 and had experienced weight loss prior to Flyte program enrollment.

Change in weight **↓ 38.8 lbs**    % change **↓ 16.9%**

Change in weight **↓ 27.9 lbs**    % change **↓ 13.1%**

\*As of 6/30/2024

# Blood Pressure

High percentage of patients enrolled with poorly controlled blood pressure

## Average Blood Pressure

At enrollment, for patients with appointments

**138.5** Systolic

**87.5** Diastolic

% of Patients with **Systolic BP ≥ 120** **84.7%**

% of Patients with **Systolic BP ≥ 130** **64.1%**

% of Patients with **Systolic BP ≥ 140** **42.6%**

% of Patients with **Diastolic BP ≥ 80** **74.8%**


% of Patients with **Diastolic BP ≥ 90** **40.1%**

n=2,645 PATIENTS

## Blood Pressure Over Time

For patients who have been enrolled ≥ 12 months and have data available

**Blood Pressure** ● SYSTOLIC PRESSURE ● DIASTOLIC PRESSURE



BLOOD PRESSURE CATEGORY	SYSTOLIC mm Hg (upper number)		DIASTOLIC mm Hg (lower number)
NORMAL	LESS THAN 120	and	LESS THAN 80
ELEVATED	120 - 129	and	LESS THAN 80
HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 1	130 - 139	or	80 - 89
HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 2	140 OR HIGHER	or	90 OR HIGHER
HYPERTENSIVE CRISIS (consult your doctor immediately)	HIGHER THAN 180	and/or	HIGHER THAN 120

change ↓ **19.28** mmHg % change ↓ **14.36%**      change ↓ **12.24** mmHg % change ↓ **14.14%**

n=169 PATIENTS

\*As of 6/30/2024



# Questions and Comments





**Adjourn**